Beclometasone dipropionate Formoterol Fumarate Glycopyrronium Bromide not checked

Chiesi Farmaceutici S.p.A. · CHF5993 · HFA-152a propellant

FollowEvery change as it happens, and a Monday email
Next date
Phase 2 trial completes
Trials
5 active
20 in total · 7 in the EU
Targets
ICS · LABA · LAMA
 

What this is

How it works
How it works isn't classified yet
How it’s given
“Beclometasone dipropionate, formoterol fumarate, and glycopyrronium bromide BDP/FF/GB (100/6/12.5 µg per actuation) administered via pressurised metered-dose inhaler (pMDI) 2 inhalations bid (i.e. 2 inhalations in the morning and 2 inhalations in the evening) for a total of 12 months.”In the company’s words, NCT07666490 on ClinicalTrials.gov
Tested for
Asthma (3 trials)
Main trialPhase 4
“This study will evaluate the effect of triple ICS/LAMA/LABA therapy with a BDP/FF/GB 100/6/12.5 µg on asthma control outcomes relative to ICS/LABA therapy with BDP/FF 200/6 μg in a population with asthma poorly controlled.”In the company’s words, NCT07666490 on ClinicalTrials.gov
Other names
CHF5993 · TRIMBOW · BDP/FF/GB · HFA-152a propellant · HFA-134a propellant · Beclometasone dipropionate · BecotideTM · CHF5993 + HFA-152a

Other drugs for Asthma

All 58 drugs for Asthma

Coming up3

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials20

TrialPhaseCompletesWhat it tests
Phase 4Recruiting 13 Jun 2028 BETRI-Prospective: Asthma Control in Single Inhaler ICS/LABA/LAMA (87/5/9 pMDI [BDP/FF/GB - 100/6/12.5 μg]) vs Single Inhaler ICS/LABA (200/6 pMDI [BDP/FF - 200/6 μg])
Phase 3Not yet recruiting 26 Jun 2030 Safety and Efficacy Comparison Between CHF5993 100/6 12.5µg pMDI to Seretide Evohaler 125/25µg pMDI in Adolescent Subjects With Asthma
Phase 2Recruiting 3 Jun 2027 Therapeutic Equivalence of CHF5993 pMDI 100/6/12.5 µg HFA-152a in Subjects With Mild to Moderate Asthma
Phase 4Completed 24 Feb 2023 CHF5993 and CHF1535 pMDI on Lung Hyperinflation and Exercise Endurance Time in Subjects With COPD
Phase 3Completed Jan 2005 Efficacy and Tolerability of Beclometasone/Formoterol Single Inhaler in Patients With Moderate to Severe Persistent Asthma
Phase 3Completed 10 Jul 2017 2-arm Parallel Group Study of Fixed Combination of CHF 5993 vs Ultibro® in COPD Patients
Phase 3Completed 17 May 2018 TRIple in asthMA With uncontRolled pAtient on Medium streNgth of ICS + LABA
Phase 3Completed 28 May 2018 TRIple in Asthma hiGh strenGth vErsus Ics/Laba hs and tiotRopium (TRIGGER)
Phase 3Completed 26 May 2020 Active Controlled Trial of CHF5993 Pressurized Metered-dose Inhaler ( pMDI) vs Symbicort®Turbuhaler® in Patients With Chronic Obstructive Pulmonary Disease ( COPD) (TRIVERSYTI)
Phase 3Completed 18 Feb 2025 Comparison Between CHF5993 pMDI 200/6/12.5 µg HFA-152a VS CHF5993 pMDI 200/6/12.5 µg HFA-134a in Subjects With Asthma (TRECOS).
Phase 2Completed 16 Oct 2018 Efficacy of Fixed Combination of Beclomethasone Dipropionate (BDP) + Formoterol Fumarate (FF) + Glycopyrronium Bromide (GB) (CHF 5993)Administered Via Dry Powder Inhaler (DPI) in Chronic Obstructive Pulmonary Disease (COPD)
Phase 1Completed Jul 2014 Drug-drug Interaction Study of CHF5993 With Cimetidine
Phase 1Completed Apr 2015 Clinical Pharmacology Study to Evaluate the Total Systemic Exposure and Lung Bioavailability of CHF 5993 pMDI Combination in Healthy Volunteers
Phase 1Completed Jul 2016 Clinical Pharmacology Study to Evaluate the Total Systemic Exposure and the Lung Availability of CHF 5993 in Healthy Volunteers
Phase 1Terminated 3 Apr 2020 Lung Deposition of TRIMBOW® pMDI in Healthy Volunteers, Asthmatic and COPD Patients
Phase 1Completed 14 Jul 2023 Clinical Study to Evaluate the Safety, Tolerability and the Concentration of the BDP (Beclomethasone Dipropionate), Active Metabolite of BDP, FF( Formoterol Fumarate) and GB (Glycopyrronium Bromide), After Inhalation of CHF 5993 at Two Different Doses and QVAR®
Phase 1Completed 13 Oct 2023 A Thorough QT (TQT) Study of CHF5993 pMDI in Healthy Volunteers (HV)
Phase 1Ended not given A single dose, randomized, double-blind, 2-way crossover clinical pharmacology study, to evaluate the lung availability and the systemic exposure of beclometasone dipropionate and beclometasone 17-monoproprionate (active metabolite of beclometasone dipropionate), after inhalation of CHF 718 pMDI HFA-152a 200 μg 4-inhalations in comparison with CHF 718 pMDI HFA-134a 200 μg 4-inhalations, using Volumatic® spacer in healthy volunteers.
Phase 4Authorised not given Inhaled corticosteroids in young children with episodic wheezing: a multicenter cluster RCT
Phase 4Authorised not given AIRITY: A hybrid cross-sectional and prospective study to assess patient characteristics, disease burden, disease control, phenotypes, endotypes, and outcomes in a real-world setting in patients with asthma
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow Beclometasone dipropionate Formoterol Fumarate Glycopyrronium Bromide

Following is part of Solo: you see every change to Beclometasone dipropionate Formoterol Fumarate Glycopyrronium Bromide the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in